Hsbc Holdings PLC Makes New Investment in Repligen Corporation $RGEN

Key Points

• Hsbc Holdings PLC has invested approximately $478,000 in Repligen Corporation, acquiring 3,780 shares in the first quarter.
• Multiple institutional investors have significantly increased their stakes in Repligen, with 97.64% of the stock now held by institutions and hedge funds.
• Analysts have mixed ratings on Repligen, with an average rating of "Moderate Buy" and a target price of $169.45, despite a recent earnings miss.

Hsbc Holdings PLC purchased a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 3,780 shares of the biotechnology company's stock, valued at approximately $478,000.

A number of other hedge funds also recently bought and sold shares of RGEN. Stifel Financial Corp raised its position in Repligen by 12.1% in the 4th quarter. Stifel Financial Corp now owns 4,939 shares of the biotechnology company's stock valued at $711,000 after purchasing an additional 535 shares in the last quarter. Northern Trust Corp raised its position in shares of Repligen by 26.0% during the 4th quarter. Northern Trust Corp now owns 493,713 shares of the biotechnology company's stock worth $71,065,000 after acquiring an additional 102,011 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Repligen during the 4th quarter worth about $844,000. Bayesian Capital Management LP acquired a new stake in shares of Repligen during the 4th quarter worth about $947,000. Finally, Bridgefront Capital LLC acquired a new stake in shares of Repligen during the 4th quarter worth about $562,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Stock Performance

NASDAQ:RGEN traded up $4.40 during mid-day trading on Thursday, reaching $120.58. 841,555 shares of the stock were exchanged, compared to its average volume of 774,246. The company has a 50 day simple moving average of $121.58 and a 200-day simple moving average of $129.76. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The stock has a market capitalization of $6.78 billion, a P/E ratio of -482.30, a P/E/G ratio of 2.25 and a beta of 1.07. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company's revenue for the quarter was up 14.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RGEN has been the topic of several research analyst reports. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Barclays initiated coverage on Repligen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price on the stock. Stephens raised Repligen to an "overweight" rating and set a $160.00 target price on the stock in a research report on Tuesday, July 22nd. HC Wainwright restated a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Wednesday. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $205.00 price target on shares of Repligen in a research note on Tuesday. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Repligen presently has an average rating of "Moderate Buy" and an average target price of $169.55.

Insider Buying and Selling at Repligen

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the purchase, the director directly owned 1,800 shares in the company, valued at $201,834. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.